For the more than four in five pancreatic cancer patients who develop cachexia, the disease has always carried a second, quieter devastation — a wasting of muscle and fat that steals the very strength needed to fight back. Researchers at the University of Oklahoma have now traced this suffering to its cellular origin, identifying three specific cell subclusters that conspire, in close physical proximity, to set cachexia in motion before a single pound of muscle is lost. The discovery, published in Cell, does not yet offer a cure, but it offers something medicine has long lacked in this domain:
Study identifies three cell clusters driving pancreatic cancer cachexia
Cachexia affects over 80% of pancreatic cancer patients, causing muscle wasting, fat loss, reduced treatment tolerance, and diminished quality of life.
These are the players driving cachexia in pancreatic cancer patients.
Mark
So they found three types of cells working together to cause this wasting. But how do we know these are actually the main drivers and not just cells that happen to be present?
Mimi
They used spatial transcriptomics to show the cells are physically adjacent to each other, forming what they call a molecular niche. The fact that they sit next to each other and form a regulatory loop suggests causation, not just correlation.
Luke
That's suggestive, but "suggests" is not the same as "proves." Have they shown that removing or blocking these cells actually stops cachexia in animal models or patients?
Mimi
The paper doesn't mention that yet. Li said their next steps are to develop strategies to target these molecules. So this is the identification phase.
Mark
Why does it matter that the subclusters form before muscle loss happens?
Mimi
Because it means there's a window to intervene before the damage is done. If you can detect these cells early, you might be able to stop cachexia before patients become too weak for treatment.
Luke
But we don't have a test for these cells yet, right? And we don't have a drug to target them yet?
Mimi
Correct. This is foundational work. It's the map. The treatment comes next.
Mark
Over 80 percent of pancreatic cancer patients get cachexia. That's a huge population.
Mimi
And there's currently no effective treatment for it. Feeding people more doesn't help. So identifying what's actually driving it is a necessary first step toward changing that.
Luke
One thing to watch: whether these three subclusters are present in all cachexic pancreatic cancer patients, or just some. If it's just some, the clinical utility is narrower.
Mark
That's a good point. Is that something the paper addresses?
Luke
The source material doesn't say. That's a question for the next phase of research.
O Pulso
- Over 80% of pancreatic cancer patients develop cachexia, a wasting syndrome that strips muscle and fat and leaves patients too weakened to endure the chemotherapy that might save them.
- Until now, no one had identified the specific cellular machinery that initiates cachexia — meaning clinicians could only watch it unfold, not anticipate or intercept it.
- University of Oklahoma researchers used single-cell sequencing and spatial transcriptomics to pinpoint three cell subclusters — SEMA4A-marked tumor cells, AQP9 macrophages, and LOXL2 fibroblasts — that form a triangular signaling loop driving cachexia forward.
- Critically, these three subclusters assemble and begin their signaling before any visible muscle or fat loss occurs, opening a potential window for early detection and intervention.
- Researchers warn that targeting cachexia alone is insufficient — tumor growth and wasting must be addressed simultaneously, or slowing one accelerates the other's damage.
- The next phase will translate this cellular map into therapeutic strategies, with the hope that early combined treatment could restore patients' capacity to tolerate — and survive — their cancer.
For the more than four in five pancreatic cancer patients who develop cachexia, the disease has always carried a second, quieter devastation — a wasting of muscle and fat that steals the very strength needed to fight back. Researchers at the University of Oklahoma have now traced this suffering to its cellular origin, identifying three specific cell subclusters that conspire, in close physical proximity, to set cachexia in motion before a single pound of muscle is lost. The discovery, published in Cell, does not yet offer a cure, but it offers something medicine has long lacked in this domain: a precise target, and a window of time in which to act.
Pancreatic cancer patients carry a double burden: the malignancy itself, and a wasting syndrome called cachexia that erodes muscle and fat until patients are too frail to tolerate the treatments that might save them. More than 80 percent of those diagnosed develop the condition, and no effective treatment currently exists. A team at the University of Oklahoma has now identified the cellular architects of this suffering — three specific cell subclusters that work in concert to trigger cachexia before any visible damage begins.
Published in Cell, the research names the key players with molecular precision: tumor cells marked by SEMA4A, macrophages carrying the AQP9 marker, and cancer-associated fibroblasts bearing LOXL2. Using single-cell sequencing and spatial transcriptomics, the researchers found that these three cell types sit physically adjacent to one another within the tumor microenvironment, forming what they describe as a molecular niche. Inside this tight space, each cell type feeds signals to the others in a loop that drives cachexia forward — a triangular regulatory network that activates before muscle wasting becomes visible, creating a critical window for early intervention.
Lead researcher Min Li, a professor of medicine at OU's College of Medicine, framed the discovery as a breakthrough in identifying who the actual drivers are, and announced plans to develop targeted strategies against all three molecules. The finding builds on Li's earlier work tracing the first steps of cachexia to crosstalk between cancer cells and macrophages, and on his "triangle regulation theory" proposing that cancer cells recruit macrophages, which then engage the central nervous system.
The clinical stakes are high. Pancreatic cancer already claims more than 87 percent of patients within five years of diagnosis. Cachexia compounds that toll by stripping patients of the physical reserves they need to endure chemotherapy. Li emphasized that any intervention must address both tumor growth and cachexia simultaneously — treating only one risks accelerating the other's damage. Robert Mannel, director of the OU Health Stephenson Cancer Center, called the discovery a meaningful step toward detecting and treating cachexia earlier, and toward restoring to patients the strength they need to fight.
Pancreatic cancer patients face a cruel double burden: the disease itself, and a wasting syndrome that strips away muscle and fat, leaving them too weak to tolerate the treatments that might save them. A team at the University of Oklahoma has now identified the cellular architects of this condition, pinpointing three specific cell subclusters that work together to trigger cachexia—and doing so before the visible damage begins.
The research, published in Cell, names the culprits with precision: tumor cells marked by SEMA4A, immune cells called macrophages that carry the AQP9 marker, and cancer-associated fibroblasts bearing LOXL2. These three cell types do not act alone. Using single-cell sequencing and spatial transcriptomics—technologies that map cells and their molecular activity at extraordinary resolution—the researchers discovered that the three subclusters sit physically adjacent to one another, forming what they call a molecular niche. Within this tight space, they form a triangular regulatory network, each cell type feeding signals to the others in a loop that drives cachexia forward.
Min Li, the lead researcher and a professor of medicine at OU's College of Medicine, described the finding as a breakthrough in understanding who the actual drivers are. "These are the players that are driving cachexia in pancreatic cancer patients," he said. "We successfully identified and isolated these small cell clusters from each cell type in the tumor microenvironment. Our next steps are to develop specific strategies to target these three molecules." The significance lies not just in naming them, but in the timing: the three subclusters form before any visible muscle or fat loss occurs, creating a window for early intervention.
Pancreatic cancer itself is among the deadliest malignancies. Fewer than 13 percent of patients survive five years after diagnosis, regardless of stage. But cachexia compounds the tragedy. More than 80 percent of pancreatic cancer patients develop the condition, and standard nutritional support cannot reverse it. Patients lose strength, appetite, and the physical reserves they need to endure chemotherapy or other treatments. The result is a vicious cycle: as cachexia progresses, patients become less able to tolerate the very therapies that might slow their cancer's growth.
Li's work builds on earlier discoveries. In 2024, he published findings showing that crosstalk between pancreatic cancer cells and macrophages marks the first step toward cachexia. Earlier this year, he advanced a "triangle regulation theory" proposing that cancer cells recruit and activate macrophages, which then engage the central nervous system. The current paper identifies the specific cell subclusters at the heart of this network and demonstrates their physical proximity—a finding that opens new diagnostic and therapeutic possibilities.
The clinical implications are immediate. If these three cell subclusters can be detected early, before cachexia manifests, physicians might intervene before patients lose the strength they need for treatment. But any such intervention would need to work in tandem with cancer therapy itself. "We need to slow down tumor growth at the same time we're slowing the progression of cachexia," Li explained. "Otherwise, if we're only lowering the burden of the tumor, patients quickly become cachexic and lose muscle strength and appetite, making them less able to withstand treatment."
Robert Mannel, director of the OU Health Stephenson Cancer Center, called the discovery an important advancement. "Cachexia has a profound impact on patients' quality of life and their ability to tolerate cancer treatment," he said. "This discovery gives us new insight into what drives cachexia and opens the door to detecting and treating it earlier." For now, there are no good treatments for cachexia—a gap that makes this identification of its cellular drivers all the more significant. The next phase will be translating this fundamental discovery into therapeutic strategies that can be tested in patients.
Citações Notáveis
We need to slow down tumor growth at the same time we're slowing the progression of cachexia. Otherwise, patients quickly become cachexic and lose muscle strength and appetite, making them less able to withstand treatment.— Min Li, lead researcher
Cachexia has a profound impact on patients' quality of life and their ability to tolerate cancer treatment. This discovery gives us new insight into what drives cachexia and opens the door to detecting and treating it earlier.— Robert Mannel, director of OU Health Stephenson Cancer Center
Quer a matéria completa?
Leia o original em News-Medical ↗